USANA Health Sciences (NYSE: USNA) reported Q3 EPS of $1.47, $0.10 better than the analyst estimate of $1.37. Revenue for the quarter came in at $191.9 million versus the consensus estimate of $190.5 million.

USANA Health Sciences sees FY2014 EPS of $5.85-$5.95, versus prior guidance of $5.5-$5.65 and the consensus of $5.53. USANA Health Sciences sees FY2014 revenue of $780-790 million, versus prior guidance of $770-790 million and the consensus of $769.5 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.